This is in line with the lower response rate of EGFR mutant NSCLCs treated with ICIs, for which low TMB was deemed to be a major culprit of low efficiency of immunotherapy for EGFR L858R NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.